Pure Global
NCT06063473

A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris

A Multi-center, Double-blind, Randomized, Placebo Controlled, Parallel-group Study, Comparing Trifarotene Cream 0.005% (Taro Pharmaceuticals U.S.A, Inc.) and to AKLIEF® Cream (Trifarotene 0.005%,Galderma) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris
Taro Pharmaceuticals USA·Phase 1·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Acne Vulgaris
Drug/Device/Intervention
Trifarotene Cream 0.005%
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Taro Pharmaceuticals USA
Location
Hawthorne, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Feb 22, 2023
End date
Jul 13, 2023
Enrollment
762 participants
Primary outcome

Demonstration in Therapeutic Equivalence & Safety of the Investigational Product

Summary

To demonstrate therapeutic equivalence and safety of Trifarotene cream 0.005% (Taro
 Pharmaceuticals U.S.A., Inc.) and AKLIEF® cream in the treatment of acne vulgaris

ICD-10 classifications
Acne vulgarisAcneAcne, unspecifiedAcné excoriéeOther acne
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06063473
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06063473 through Pure Global AI's free database. This Phase 1 trial is sponsored by Taro Pharmaceuticals USA and is currently Completed. The study focuses on Acne Vulgaris. Target enrollment is 762 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.